Verapamil and low-dose anti-mouse thymocyte globulin combination therapy stably reverses recent-onset type 1 diabetes in NOD mice by acting on the beta cell and immune axes
The combination of verapamil and low-dose mATG outperformed monotherapy in reversing recent-onset type 1 diabetes in NOD mice. This approach targets both the beta cell and immune axes, suggesting a promising strategy for disease reversal in human type 1 diabetes.
Authors
- Conny Gysemans (ORCID: https://orcid.org/0000-0003-3559-6089)
- Willem Staels (ORCID: https://orcid.org/0000-0001-8259-3329)
- Marijke Viaene
- Nico De Leu (ORCID: https://orcid.org/0000-0002-0542-5708)
- Nick Geukens (ORCID: https://orcid.org/0000-0001-5706-1072)
- Yves Heremans (ORCID: https://orcid.org/0000-0002-2608-974X)
- Laure Degroote (ORCID: https://orcid.org/0000-0001-7310-6103)
- Pieter-Jan Martens (ORCID: https://orcid.org/0009-0009-3133-7507)
- Gunter Leuckx (ORCID: https://orcid.org/0000-0003-2732-397X)
Institutions
- Vrije Universiteit Brussel (BE)
- Onze Lieve Vrouwziekenhuis Hospital (BE)
- Universitair Ziekenhuis Brussel (BE)
- Flanders Environment Agency (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Diabetologia
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1007/s00125-025-06490-8
- Citations
- 2
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- Vertex Pharmaceuticals
- European Federation of Pharmaceutical Industries and Associations
- Insulet Corporation
- MannKind Corporation
- European Commission
- Fonds Wetenschappelijk Onderzoek
- KU Leuven
- Novo Nordisk
- European Association for the Study of Diabetes
- Vlaamse regering
- H2020 Health